Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 12/2019

Open Access 01-12-2019 | Clear-Cell Sarcoma | Original Article

Prognostic analysis of surgically treated clear cell sarcoma: an analysis of a rare tumor from a single center

Authors: Shiqi Chen, Peng Luo, Lingge Yang, Biqiang Zheng, Zhengwang Sun, Wangjun Yan, Chunmeng Wang

Published in: International Journal of Clinical Oncology | Issue 12/2019

Login to get access

Abstract

Background

The objective of this retrospective study was to evaluate the prognostic value of various factors in clear cell sarcoma patients after radical surgery.

Methods

Forty-two clear cell sarcoma patients from August 2006 to March 2018 were included in the study. Curves of disease-free survival and overall survival were calculated using the Kaplan–Meier method, and univariate and multivariate analyses of various prognostic factors were performed using a Cox proportional hazard regression model. Laboratory test of peripheral blood was recorded before surgery. The optimal cutoff value of systemic inflammatory markers was defined by receiver-operating curve analysis.

Results

The 5-year DFS and 5-year OS rate were 22% and 46%, respectively. The median DFS and OS times were 12 and 41.5 months, respectively. In univariate analysis, there was a significant association between shorter DFS and tumor size larger than 5 cm (p = 0.0043), positive surgical margin (p = 0.0233), and the neutrophil-to-lymphocyte ratio (NLR) higher than 2.73 (p = 0.0009). Furthermore, we observed a significant association between shorter OS and tumor size larger than 5 cm (p = 0.0075), positive surgical margin (p = 0.0101), NLR higher than 2.73 (p = 0.0126), the platelet-to-lymphocyte ratio (PLR) higher than 103.89 (p = 0.0147) and the lymphocyte-to-monocyte ratio (LMR) lower than 4.2 (p = 0.0445). A multivariate analysis demonstrated that the surgical margin (p = 0.013) and NLR (p = 0.001) were significantly associated with DFS. Tumor size (p = 0.010) and NLR (p = 0.013) were independent prognostic factors for OS.

Conclusions

This study had the second largest sample around the world and preoperative NLR may be a useful prognostic factor in CCS patients after radical surgery.
Literature
1.
Enzinger FM (1965) Clear-cell sarcoma of tendons and aponeuroses. An analysis of 21 cases. 18:1163–1174.
2.
Hoffman GJ, Carter D (1973) Clear cell sarcoma of tendons and aponeuroses with melanin. Arch Pathol 95:22–25PubMed
3.
Yang L, Chen Y, Cui T et al (2012) Identification of biomarkers to distinguish clear cell sarcoma from malignant melanoma. Hum Pathol 43:1463–1470CrossRef
4.
Mavrogenis A, Bianchi G, Stavropoulos N et al (2013) Clinicopathological features, diagnosis and treatment of clear cell sarcoma/melanoma of soft parts. Hippokratia 17:298–302PubMedPubMedCentral
5.
Yoon JH, Baek YS, Jeon J et al (2014) Dual-color, break-apart fluorescence in situ hybridization probe for distinguishing clear cell sarcoma of soft tissue from malignant melanoma. Int J Dermatol 53:1464–1467CrossRef
6.
Malchau SS, Hayden J, Hornicek F et al (2007) Clear cell sarcoma of soft tissues. J Surg Oncol 95:519–522CrossRef
7.
Kosemehmetoglu K, Folpe AL (2010) Clear cell sarcoma of tendons and aponeuroses, and osteoclast-rich tumour of the gastrointestinal tract with features resembling clear cell sarcoma of soft parts: a review and update. J Clin Pathol 63:416–423CrossRef
8.
Clark MA, Johnson MB, Thway K et al (2008) Clear cell sarcoma (melanoma of soft parts): the Royal Marsden Hospital experience. Eur J Surg Oncol 34:800–804CrossRef
9.
Kawai A, Hosono A, Nakayama R et al (2007) Clear cell sarcoma of tendons and aponeuroses: a study of 75 patients. Cancer 109:109–116CrossRef
10.
Bianchi G, Charoenlap C, Cocchi S et al (2014) Clear cell sarcoma of soft tissue: a retrospective review and analysis of 31 cases treated at Istituto Ortopedico Rizzoli. Eur J Surg Oncol 40:505–510CrossRef
11.
Liang W, Ferrara N (2016) The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunol Res 4:83–91CrossRef
12.
Swierczak A, Mouchemore KA, Hamilton JA et al (2015) Neutrophils: important contributors to tumor progression and metastasis. Cancer Metastasis Rev 34:735–751CrossRef
13.
Asaoka T, Miyamoto A, Maeda S et al (2016) Prognostic impact of preoperative NLR and CA19-9 in pancreatic cancer. Pancreatology 16:434–440CrossRef
14.
Chan JY, Zhang Z, Chew W et al (2018) Biological significance and prognostic relevance of peripheral blood neutrophil-to-lymphocyte ratio in soft tissue sarcoma. Sci Rep 8:11959CrossRef
15.
Ethier JL, Desautels D, Templeton A et al (2017) Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis. Breast Cancer Res 19:2CrossRef
16.
Li MX, Liu XM, Zhang XF et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer 134:2403–2413CrossRef
17.
Dim DC, Cooley LD, Miranda RN (2007) Clear cell sarcoma of tendons and aponeuroses: a review. Arch Pathol Lab Med 131:152–156PubMed
18.
Lee HL, Ho WY, Lam YL et al (2014) Prognostic factors associated with clear cell sarcoma in 14 Chinese patients. J Orthop Surg (Hong Kong) 22:236–239CrossRef
19.
Blazer DG 3rd, Lazar AJ, Xing Y et al (2009) Clinical outcomes of molecularly confirmed clear cell sarcoma from a single institution and in comparison with data from the surveillance, epidemiology, and End Results registry. Cancer 115:2971–2979CrossRef
20.
Hocar O, Le Cesne A, Berissi S et al (2012) Clear cell sarcoma (malignant melanoma) of soft parts: a clinicopathologic study of 52 cases. Dermatol Res Pract 2012:984096CrossRef
21.
Szkandera J, Gerger A, Liegl-Atzwanger B et al (2015) The derived neutrophil/lymphocyte ratio predicts poor clinical outcome in soft tissue sarcoma patients. Am J Surg 210:111–116CrossRef
22.
Azab B, Mohammad F, Shah N et al (2014) The value of the pretreatment neutrophil lymphocyte ratio vs. platelet lymphocyte ratio in predicting the long-term survival in colorectal cancer. Cancer Biomark 14: 303-312.CrossRef
23.
Gao F, Li X, Geng M et al (2015) Pretreatment neutrophil-lymphocyte ratio: an independent predictor of survival in patients with hepatocellular carcinoma. Medicine (Baltimore) 94:e639CrossRef
24.
Goh BK, Chok AY, Allen JC Jr et al (2016) Blood neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios are independent prognostic factors for surgically resected gastrointestinal stromal tumors. Surgery 159:1146–1156CrossRef
25.
Lieto E, Galizia G, Auricchio A et al (2017) Preoperative Neutrophil to lymphocyte ratio and lymphocyte to monocyte ratio are prognostic factors in gastric cancers undergoing surgery. J Gastrointest Surg 21:1764–1774CrossRef
26.
Liu G, Ke LC, Sun SR (2018) Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in patients with soft tissue sarcoma: A meta-analysis. Medicine (Baltimore) 97:e12176CrossRef
27.
Szkandera J, Absenger G, Liegl-Atzwanger B et al (2013) Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients. Br J Cancer 108:1677–1683CrossRef
28.
Templeton AJ, McNamara MG, Seruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106:dju124.CrossRef
29.
Zhang H, Xia H, Zhang L et al (2015) Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer. Am J Surg 210:526–535CrossRef
30.
Que Y, Qiu H, Li Y et al (2015) Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma. BMC Cancer 15:648CrossRef
31.
Szkandera J, Gerger A, Liegl-Atzwanger B et al (2014) The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int J Cancer 135:362–370CrossRef
32.
Powell DR, Huttenlocher A (2016) Neutrophils in the tumor microenvironment. Trends Immunol 37:41–52CrossRef
33.
Ocana A, Nieto-Jimenez C, Pandiella A, Templeton AJ (2017) Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer 16:137CrossRef
34.
Geng Y, Shao Y, He W et al (2015) Prognostic role of tumor-infiltrating lymphocytes in lung cancer: a meta-analysis. Cell Physiol Biochem 37:1560–1571CrossRef
35.
Stanton SE, Disis ML (2016) Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer 4:59CrossRef
36.
Dirican N, Karakaya YA, Gunes S et al (2017) Association of intra-tumoral tumour-infiltrating lymphocytes and neutrophil-to-lymphocyte ratio is an independent prognostic factor in non-small cell lung cancer. Clin Respir J 11:789–796CrossRef
37.
Marcrom S, De Los Santos JF, Conry RM (2017) Complete response of mediastinal clear cell sarcoma to pembrolizumab with radiotherapy. Clin Sarcoma Res 7:14CrossRef
Metadata
Title
Prognostic analysis of surgically treated clear cell sarcoma: an analysis of a rare tumor from a single center
Authors
Shiqi Chen
Peng Luo
Lingge Yang
Biqiang Zheng
Zhengwang Sun
Wangjun Yan
Chunmeng Wang
Publication date
01-12-2019
Publisher
Springer Singapore
Published in
International Journal of Clinical Oncology / Issue 12/2019
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-019-01487-x

Other articles of this Issue 12/2019

International Journal of Clinical Oncology 12/2019 Go to the issue

Original Article

Clinical impact of periodontal disease on postoperative complications in gastrointestinal cancer patients

Original Article

Treatment-associated outcomes of patients with primary ocular adnexal MALT lymphoma after accurate diagnosis

Original Article

An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer

Original Article

Prognostic relevance of ATM protein in uveal melanoma and its association with clinicopathological factors

Original Article

Phonatory function in patients with well-differentiated thyroid carcinoma following meticulous resection of tumors adhering to the recurrent laryngeal nerve

Original Article

A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits